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erance (SI) in an administrative database using electronic medical
records (EMRs) as the reference comparison. Methods: One thousand
adults with one or more qualifying changes in statin therapy and one
or more previous diagnoses of hyperlipidemia, hypercholesterolemia,
or mixed dyslipidemia were identiﬁed from the Henry Ford Health
System administrative database. Data regarding statin utilization,
comorbidities, and adverse effects were extracted from the admin-
istrative database and corresponding EMR. Patients were stratiﬁed by
cardiovascular (CV) risk. SI was classiﬁed as absolute intolerance
or titration intolerance on the basis of changes in statin utilization
and/or the occurrence of adverse effects and laboratory testing for
creatine kinase. Measures of concordance (Cohen’s kappa [κ]) and
accuracy (sensitivity, speciﬁcity, positive predictive value [PPV], and
negative predictive value) were calculated for the administrative
database algorithms. Results: Half of the sample population was
white, 52.9% were women, mean age was 60.6 years, and 35.7% were
at high CV risk. SI was identiﬁed in 11.5% and 14.0%, absolute
intolerance in 2.2% and 3.1%, and titration intolerance in 9.7% andee front matter Copyright & 2016, International S
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respectively. The algorithm identifying any SI had substantial concord-
ance (κ ¼ 0.66) and good sensitivity (78.1%), but modest PPV (64.0%). The
titration intolerance algorithm performed better (κ ¼ 0.74; sensitivity
85.4%; PPV 70.1%) than the absolute intolerance algorithm (κ ¼ 0.40;
sensitivity 50%; PPV 35.5%) and performed best in the high CV-risk
group (n ¼ 353), with robust concordance (κ ¼ 0.73) and good sensitivity
(80.9%) and PPV (75.3%). Conclusions: Conservative but comprehensive
algorithms are available to identify SI in administrative databases for
application in real-world research. These are the ﬁrst validated algo-
rithms for use in administrative databases available to decision makers.
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Research has consistently demonstrated that statins decrease
both the risk for cardiovascular (CV) events and mortality rates in
patients with hypercholesterolemia [1,2]. Consequently, contem-
porary lipid management guidelines recommend statin therapy
for patients with increased CV risk who are most likely to beneﬁt
in terms of atherosclerotic cardiovascular disease (ASCVD) risk
reduction. The American College of Cardiology/American Heart
Association guidelines identify four major statin beneﬁt groups:
1) individuals with clinical ASCVD, 2) individuals with elevated
low-density lipoprotein cholesterol (LDL-C; Z190 mg/dl), 3) indi-
viduals with diabetes and increased LDL-C (70–189 mg/dl), and4) individuals with estimated 10-year ASCVD risk of 7.5% or
higher [3]. The National Lipid Association (NLA) recommends
moderate- to high-intensity statin therapy for patients with
ASCVD or diabetes mellitus, regardless of baseline lipid levels [4].
Despite the known beneﬁts of statins, many patients, includ-
ing those at high CV risk, discontinue treatment [5]. Experiencing
statin-related adverse effects (AEs) is one of the most common
reasons for statin switching or discontinuation [6]. Even among
adherent patients, providers may not always be able to prescribe
the preferred therapeutic dose as AE frequency increases with
dose intensity [7,8]. The most common statin-associated AEs are
muscle-related, and these have been documented in 16.0% to
32.9% of patients receiving statins and in 15.4% to 33.2% ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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[9]. A number of other AEs, however, have been associated with
statin therapy, including elevated transaminase, headache,
insomnia, fatigue, dyspepsia, nausea, rash, alopecia, constipa-
tion, diarrhea, gastrointestinal disturbance, arthritis, and renal
disorders [10–12]. Studies have estimated the incidence or prev-
alence of muscle-related symptoms (5%–25%), but these data are
from clinical trials, single-site retrospective cohort studies, and
patient surveys and as such may have limited generalizability to
the larger population [6,13–18]. Factors associated with increased
risk of statin intolerance (SI) include advanced age, clinical or
subclinical hypothyroidism, and pre-existing liver or chronic
kidney disease [19].
Although SI is recognized as a clinical entity, there is no
consensus yet on a single deﬁnition [19,20], making it difﬁcult to
assess the incidence of SI. The Canadian Working Group (CWG)
has deﬁned SI as a clinical syndrome
characterized by inability to use statins for long-term reduc-
tion of lipids and/or CV risk because of signiﬁcant symptoms
and/or biomarker abnormalities that can be temporally attrib-
uted to the initiation or dose escalation of statins; if appro-
priate, drug withdrawal and rechallenge can strengthen the
association. [21(p1553)]
The NLA deﬁnes SI as
a clinical syndrome characterized by the inability to tolerate at
least 2 statins: one statin at the lowest starting daily dose AND
another statin at any daily dose, due to either objectionable
symptoms (real or perceived) or abnormal lab determinations,
which are temporally related to statin treatment and reversible
upon statin discontinuation, but reproducible by re-challenge,
with other known determinants being excluded. [22(pS78)]
These deﬁnitions, although similar in many respects, differ in
terms of mandating statin dosage and rechallenge and also with
respect to the validity of patient symptoms.
Accurate identiﬁcation of SI is important in terms of both
establishing its incidence and characterizing the associated
clinical, economic, and quality-of-life burdens, which are at
present unknown. The objective of this study was to develop
and validate algorithms to identify patients with SI in an admin-
istrative database on the basis of the overlap between CWG and
NLA deﬁnitions.Methods
Data Source
The data source selected to develop and validate the SI algo-
rithms was from the Henry Ford Health System (HFHS). The HFHS
offers primary, acute, and specialty care services in the Midwest
and also includes a wholly owned nonproﬁt health maintenance
organization, the Health Alliance Plan (HAP). HFHS data reposi-
tories include both an administrative database, which provides
comprehensive medical billing and pharmacy claims data, and
electronic medical records (EMRs), including laboratory results,
from all sites of service, linkable for each patient using a lifetime
patient identiﬁer. This study was approved by the HFHS institu-
tional review board.
Validation Study Sample
The validation study sample was drawn from the HFHS admin-
istrative claims database using the following criteria: adults (Z18
years) who 1) had one or more statin qualifying events between
December 1, 2005, and November 30, 2010, 2) were continuouslyenrolled in HAP for 1 year before and 2 years after the qualifying
event, and 3) had one or more diagnoses (International Classiﬁca-
tion of Diseases, Ninth Revision, Clinical Modiﬁcation [ICD-9-CM]) of
hyperlipidemia (272.4), hypercholesterolemia (272.0), or mixed
hyperlipidemia (272.2) before the qualifying event (index) because
lipid levels may have been inﬂuenced by existing statin therapy.
Qualifying events included statin discontinuation, switch, or a
decrease in statin dosage. Statin switch events were eligible only
if the patient switched from a high-intensity statin to a lower
intensity statin or from a moderate/low-intensity statin to
another moderate/low-intensity statin. Deﬁnitions of moderate/
low-intensity and high-intensity statins were based on LDL-C–
lowering capability. A statin was considered of high intensity or
high potency if it reduced the LDL-C level from baseline by more
than 45% (Table 1) [23,24].
If a patient had multiple qualifying events, the ﬁrst qualifying
event that met the eligibility criteria was selected. If the statin
medication pattern for an individual patient met the criteria for
both moderate/low-intensity and high-intensity statins, only the
high-intensity qualiﬁer was selected, although this did not
exclude evaluation of the low-intensity statin if it also occurred
during the study observation window. Study index was the date
of each qualifying event. All patients were observed for 1 year
pre- and 2 years postindex.
A sample of 1000 patients was drawn from the pool of eligible
patients. Patients were categorized as being at high CV risk if they
had two or more ICD-9-CM diagnoses of diabetes, coronary heart
disease, or peripheral artery disease in the 12 months before the
qualifying event on outpatient claims on different days or a
single diagnosis on an inpatient claim. Data on patients’ demo-
graphic and clinical characteristics, statin utilization, and AEs
were extracted electronically from the administrative database.
Statin utilization and AEs data were simultaneously abstracted
from the EMR by three trained and credentialed research asso-
ciates, after completion of a pilot study. Patients with unresolv-
able conﬂicts in the EMR or data quality issues in pharmacy
claims were excluded from the study.Statin Utilization and AEs
Statin exposure windows were created to characterize statin
utilization and to identify associated AEs. Exposure windows were
created independently on the basis of the statin regimen (statin
plus dose) prescribed in the EMR as well as on statin ﬁll records
from pharmacy data in the administrative database. If present
during an exposure window, SI was identiﬁed and conﬁrmed.
The following information was abstracted from the EMR: statin
prescription dates and dosage, AE type and date, whether changes
in prescription were linked to an AE, and the primary and
secondary reasons for statin discontinuation or dose lowering, if
applicable. A prescription was end-dated if there was an absence of
documentation for more than 12months. Prescription records were
then collapsed if the statin name and dosage were unchanged.
Statin exposure windows based on the administrative data
relied on pharmacy claims. Periods of continuous use for each
statin regimen were identiﬁed, allowing for a 30-day gap in the
daily drug coverage pattern. In addition, a 45-day grace period
was appended to the end of the exposure window for each statin
regimen to account for verbal changes in physician instruction
that were not reﬂected in the pharmacy claims records.
A list of AEs (primary and secondary) related to statin use was
compiled (Table 2) [10–12]. The occurrence of an AE was based on
the documentation of either the clinical term or the ICD-9-CM
diagnosis code for an eligible AE in the EMR and independently
based solely on the documentation of an ICD-9-CM diagnosis code
for one of the eligible AEs in administrative data.
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The reference deﬁnition of SI was based on EMR data. The SI
algorithms were based only on administrative data. Statin-
intolerant patients identiﬁed by the administrative database
algorithms were then compared with those identiﬁed by the
EMR reference, and performance of the algorithms was eval-
uated. The EMR was presumed to be a superior source of
information about SI, given the richness of its clinical repository
(e.g., text-based ofﬁce notes with symptom information). In the
primary analysis, the complete list of potential AEs was included
in the deﬁnition of SI, whereas the secondary analysis included
only musculoskeletal events (Table 2).
All patients, in both data sources, were classiﬁed as absolute
statin-intolerant (unable to tolerate any exposure to statins) or
titration statin-intolerant (maximum tolerated dosage less than
the desired therapeutic dosage). Patients in the study could meet
the criteria for both absolute and titration intolerance.
The occurrence of absolute intolerance was predicated on the
notion that patients must be rechallenged with a second statin
unless the documented AE was rhabdomyolysis, a potentially
life-threatening syndrome resulting from the breakdown of
skeletal muscle ﬁbers and subsequent release of cellular content
into the circulation [25]. Accordingly, in the EMR, absolute intol-
erance required the following three criteria to be satisﬁed: 1) the
physician discontinues two or more prescriptions for different
statin agents (only one in the presence of rhabdomyolysis), 2) the
patient never receives another statin prescription (minimum of
100 days of observation remaining postdiscontinuation), and
3) the reason for discontinuation (primary or secondary) is an
AE, or an explicit link is documented between the statin and an
AE, or the patient is documented as statin-intolerant/allergic.
The absolute intolerance algorithm applied to the adminis-
trative database also reﬂected these principles, requiring that
1) the patient stops ﬁlling prescriptions for two or more statin
agents (only one in the presence of rhabdomyolysis), 2) the
patient never ﬁlls another statin prescription (minimum of 100
days of observation remaining), and 3) either an elevated creatine
kinase test result or an AE is documented during exposure to the
last documented statin.
The occurrence of titration SI was predicated on the supposi-
tion that, among patients on high-intensity statin therapy, any
reduction in intensity reﬂects the inability of the patient to
tolerate the desired therapeutic statin strength. Accordingly, in
the EMR, titration intolerance required the following three criteria
to be satisﬁed: 1) the physician discontinues a prescription for a
high-intensity statin and initiates a prescription at a lower level
of intensity, 2) either the discontinued high-intensity statin is
linked to SI or there is an AE documented during the period of
high-intensity exposure, and 3) there is no subsequent prescrip-
tion for a statin at the original intensity level (minimum of 100
days of observation remaining).
The titration intolerance algorithm that was applied to the
administrative database also embodied these principles, requiring
that 1) the patient discontinues ﬁlling a prescription for a high-
intensity statin and ﬁlls a prescription at a lower level of intensity,
2) no subsequent prescription is ﬁlled for a statin at the original
intensity level, and 3) there is a minimum of 100 days remaining in
the observation window after the lowering of the statin intensity.
Data Analysis
The EMR served as the reference against which the algorithms
were evaluated, as is customary in administrative data–based
validation studies. Concordance between the reference and the
algorithms was measured using Cohen’s kappa (κ), a numerical
rating of the degree to which the observers (or data sources) agree
by chance. Kappa is standardized on a scale of 1 to 1, where
Table 2 – Deﬁnition of statin-related AEs.
AE Clinical term ICD-9-CM code
Musculoskeletal AEs/side effects
Myalgia and/or
myositis
Muscle pain, spasm, weakness, discomfort,
soreness, cramps, or aching
728.85 (spasm of muscle); 729.82 (cramp in limb);
728.87 (muscle weakness-generalized); 729.1x
(myalgia and myositis, unspeciﬁed)
Arthralgia Joint pain, joint stiffness 719.4x (pain in joint); 719.5x (stiffness in joint)
Rhabdomyolysis Rhabdomyolysis 728.88 (rhabdomyolysis)
Myopathy Myopathy, toxic myopathy 359.4 (toxic myopathy); 359.89 (other myopathy);
359.9 (myopathy, unspeciﬁed)
Other muscle
toxicity
Limb pain, ligament pain, fascia pain, limb
discomfort, other drug poisoning
728.9x (unspeciﬁed disorder of muscle, ligament,
and fascia); 729.1x (pain in limb); E980.4 (injury
from other speciﬁed drugs)
Elevated CPK CPK 45 ULN
Gastrointestinal-related AEs/side effects
Nausea Nausea, vomiting 787.0 (nausea and/or vomiting)
Constipation Constipation 564.0 (constipation)
Diarrhea Diarrhea 564.5 (functional diarrhea); 787.91 (diarrhea)
Other
gastrointestinal
distress
Flatulence, gas, bloating, abdominal pain,
gastritis, duodenitis
787.3 (ﬂatulence, eructation, and gas pain); 789.0
(abdominal pain); 535 (gastritis and
duodenitis)
Other AEs/side effects
Anaphylaxis Anaphylactic shock 995.0 (other anaphylactic shock)
Rash/facial
ﬂushing
Urticaria, angioedema, rash, hives, dermatitis,
edema, erythema, rosacea, facial ﬂushing,
pruritus
782.1 (rash and other nonspeciﬁc skin eruption);
708.0 (allergic urticaria); 693.0 (dermatitis due
to drugs/medicines); 995.1 (angioneurotic
edema); 995.2 (other and unspeciﬁed AE of
drug, medicinal, and biological substance (due)
to correct medicinal substance properly
administered); 695.1 (erythema multiforme);
698 (pruritus and related conditions); 695.3
(rosacea)
Cognitive
impairment
Memory loss, forgetfulness, confusion 331.83 (mild cognitive impairment, so stated);
780.93 (memory loss); 799.51 (attention or
concentration deﬁcit)
Elevated LFT LFT 43 ULN
Note. Intolerance deﬁnition: The primary analysis included the complete list of potential AEs in the deﬁnition of SI, whereas the secondary
analysis included only musculoskeletal events.
AEs, adverse effects; CPK, creatine phosphokinase; ICD-9-CM, International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation; LFT, liver
function test; ULN, upper limit of normal.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 5 2 – 8 6 0 8551 represents perfect agreement, 0 represents what would be
expected by chance, and negative values indicate agreement less
than chance [26]. A kappa statistic between 0.41 and 0.60 was used
to indicate moderate agreement, 0.61 to 0.80 substantial agree-
ment, and 0.81 to 1.0 almost perfect agreement [27]. In addition, we
used traditional tests of diagnostic accuracy to measure the
sensitivity, speciﬁcity, positive predictive value (PPV), and negative
predictive value (NPV) of the algorithms. The algorithms were
reﬁned to incorporate new information and expert opinions after
the entire medical record was reviewed for patients identiﬁed by
the algorithms as false-positive or false-negative. The deﬁnitions of
SI used in the administrative database were subsequently revised
to maximize the agreement with the NLA deﬁnition of SI [22] and
to maximize the concordance and accuracy of the algorithms. Only
the ﬁnal versions of the algorithms are presented.Results
Patient Disposition and Characteristics
A total of 46,783 patients enrolled in the HAP were prescribed
a statin between December 1, 2004, and November 30, 2012.Figure 1 details accrual into the pool of eligible patients. A total
of 1000 patients were selected to be included in the ﬁnal
validation sample on the basis of the observed distribution
(80/20) of moderate/low-intensity and high-intensity statins. To
adjust for HFHS-speciﬁc formulary restrictions, a higher percent-
age of atorvastatin patients (40%) and a lower percentage of
simvastatin patients (40%) than observed in the pool of eligible
patients were selected to reﬂect real-world statin use. The
remaining 20% of selected patients represent the use of other
statins. Because of irreconcilable differences in the medical
records, 10 patients (1%) were excluded from the study after data
abstraction.
Table 3 presents the baseline demographic and clinical charac-
teristics of the sample. Half of the sample population was white
(49.8%) and half was female (52.9%). Twenty-ﬁve percent of the
patients resided in an area where the median household income
was less than $40,000, whereas 20.6% resided in an area where the
median household income was $70,000 or more. Prescriptions for
nonstatin lipid-lowering therapy were used infrequently. A total of
353 patients (36%) had baseline evidence of diabetes (27.4%),
coronary artery disease (11.7%), or peripheral artery disease (0.6%)
and were classiﬁed as having high CV risk. Hypertension was the
most common comorbidity, identiﬁed in 39.9% of the patients at
Study sample (n=1000)†‡
• Moderate- to low-intensity statin (n=800)
• Statin discontinuation (n=287)
• Switch to another moderate- to low-intensity 
statin (n=403)
• Dose decrease (n=110)
• High-intensity statin (n=200)
• Statin discontinuation (n=37)
• Switch to another moderate- to low-intensity 
statin (n=87)
• Dose decrease (n=76)
Patients with ≥1 statin prescription (n=46,783)
Patients with complete pharmacy data and a guideline-
based dosing regimen (n=38,343)
Reasons for exclusion:
• No diagnosis of hyperlipidemia, 
hypercholesterolemia, or mixed hyperlipidemia 
(n=2662)
• Lack of continuous enrollment in HAP (n=6586)
• Qualifying event outside of the selection 
window (12/1/2005-11/30/2010) (n=128)
Patients with study-eligible qualifying event (n=14,849)
Patients with a qualifying event during the selection 
window (12/1/2005-11/30/2010) (n=5473) 
• Change in moderate- to low-intensity statin therapy 
(n=4372)
• Statin discontinuation (n=2067)
• Switch to another moderate- to low-intensity 
statin (n=1471)
• Dose decrease (n=834)
• Change in high-intensity statin (n=1101)*
• Statin discontinuation (n=196)
• Switch to a lower intensity statin (n=475)
• Dose decrease (n=430)
High CV-risk patients (n=353)§
Low CV-risk patients (n=637)
Fig. 1 – Patient disposition. CV, cardiovascular risk; HAP, Health Alliance Plan. *High-intensity statin: atorvastatin 40 or 80 mg;
rosuvastatin 10, 20, or 40 mg; and simvastatin 80 mg. †Patients were selected randomly to preserve the 80/20 split between
moderate- to low-intensity and high-intensity statin patients observed in the administrative database, with 40% on simvastatin,
40% on atorvastatin, and 20% on other statins. ‡Ten patients were excluded because of data quality issues. §Patients with a
diagnosis of diabetes, coronary heart disease, or peripheral artery disease in the 12 mo before the qualifying event.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 5 2 – 8 6 0856baseline. In the EMR, the most frequent AEs documented during an
episode of statin exposure that was classiﬁed as intolerant were
other muscle toxicity (19.8%), myalgia or myositis (18.4%), arthralgia
(12.8%), and rash (11.3%) (see Table in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2016.03.1858).
SI and Algorithm Concordance
In the primary analysis, 11.5% of the patients (n ¼ 114) were
identiﬁed in the EMR as statin-intolerant compared with 14.0% of
the patients (n ¼ 139) in the administrative database (Table 4).
The proportion of patients identiﬁed as statin-intolerant was
twice as high among patients at high CV risk as it was among
those at low CV risk. Titration intolerance occurred in 16.7% and
5.8% of the patients in the EMR and in 18.7% and 8.0% of the
patients in the administrative database in high and low CV-risk
groups, respectively. Few patients were identiﬁed as absolute
intolerant in either high or low CV-risk groups. The frequency of
SI in the secondary analysis was lower but not notably so
(Table 5). It should be noted that these frequencies cannot beused as proxies for SI incidence in the general population because
the study was not conducted on a random sample of statin users.
Although rates of SI in the EMR and the administrative database
were similar, the algorithms did not always identify the same
patients as intolerant. Generally, the algorithm identifying any SI
demonstrated high levels of overall agreement (92.4%), substantial
concordance (κ ¼ 0.66), and good sensitivity (78.1%), but modest PPV
(64.0%), reﬂecting differences in the accuracy of the algorithm
associated with detecting absolute and titration intolerance. The
absolute intolerance algorithm had notably lower concordance (κ ¼
0.30–0.56), sensitivity (46%–55%), and PPV (24%–60%) both overall and
in each of the CV-risk groups. Both absolute and titration intolerance
algorithms performed best in the high CV-risk group. In the high CV-
risk group, the titration intolerance algorithm was most robust, with
overall agreement at 93.5%, substantial concordance (κ ¼ 0.78), and
good PPV (77.3%). The titration intolerance algorithm in the low
CV-risk cohort also showed substantial concordance (κ ¼ 0.68) and
good sensitivity (83.8%), but modest PPV (60.8%). NPV was uniformly
high, ranging from 95% to 99%. Although the frequency of SI in the
secondary analysis was similar to that in the primary analysis,
Table 3 – Patients’ demographic and clinical characteristics at baseline.
Characteristic High CV-risk patients
(n ¼ 353)
Low CV-risk patients
(n ¼ 637)
All patients
(N ¼ 990)
Sex: male, n (%) 183 (51.8) 283 (44.4) 466 (47.1)
Age (y), mean  SD at index 62.6  12.4 59.5  12.2 60.6  12.4
Race, n (%)
White 154 (43.6) 339 (53.2) 493 (49.8)
Black 136 (38.5) 171 (26.8) 307 (31.0)
Asian 9 (2.5) 16 (2.5) 25 (2.5)
Others 54 (15.3) 111 (17.4) 165 (16.7)
Medical history, n (%)
Abdominal aortic aneurysm 1 (0.3) 2 (0.3) 3 (0.3)
Carotid artery disease 3 (0.8) 2 (0.3) 5 (0.5)
Chronic kidney disease 21 (5.9) 10 (1.6) 31 (3.1)
CHD/CAD 116 (32.9) – 116 (11.7)
Diabetes 271 (76.8) – 271 (27.4)
Hypertension 195 (55.2) 200 (31.4) 395 (39.9)
PAD 6 (1.7) – 6 (0.6)
Qualifying statin medication, n (%)
Atorvastatin 122 (34.6) 275 (43.2) 397 (40.1)
Fluvastatin 1 (0.3) 3 (0.5) 4 (0.4)
Lovastatin 39 (11.0) 58 (9.1) 97 (9.8)
Pitavastatin 0 (0.0) 0 (0.0) 0 (0.0)
Pravastatin 19 (5.4) 34 (5.3) 53 (5.4)
Rosuvastatin 23 (6.5) 19 (3.0) 42 (4.2)
Simvastatin 149 (42.2) 248 (38.9) 397 (40.1)
Qualifying statin event, n (%)
Dose decrease in existing therapy 89 (25.2) 95 (14.9) 184 (18.6)
High-intensity* to moderate- to low-intensity switch 42 (11.9) 45 (7.1) 87 (8.8)
Moderate- to low-intensity to another moderate-
to low-intensity switch
124 (35.1) 274 (43.0) 398 (40.2)
Stopped statin therapy altogether 98 (27.8) 223 (35.0) 321 (32.4)
Other prescribed LLT†, n (%) 62 (17.6) 47 (7.4) 109 (11.0)
Lab results (mg/dl), mean  SD
LDL-C 102.1  35.8 123.5  39.6 115.5  39.6
HDL-C 52.2  15.7 57.2  15.9 55.3  16.0
Triglycerides 156.4  85.8 156.0  85.5 156.2  85.5
Total cholesterol 184.9  43.8 211.6  45.1 201.7  46.4
AST 29.0  50.4 25.1  11.4 26.5  32.3
ALT 33.9  40.7 31.3  16.9 32.3  28.4
Creatine kinase 483.3  2549.7 260.5  539.2 360.1  1748.3
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAD, coronary artery disease; CHD, coronary heart disease; CV,
cardiovascular; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PAD,
peripheral artery disease.
* High-intensity statin: atorvastatin 40 or 80 mg; rosuvastatin 10, 20, or 40 mg; and simvastatin 80 mg.
† Other prescribed LLTs included cholestyramine, cloﬁbrate, colesevelam, colestipol, ezetimibe, fenoﬁbrate, fenoﬁbric acid, gemﬁbrozil, niacin,
omega-3-acid ethyl esters, and probucol.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 5 2 – 8 6 0 857performance was diminished for both absolute intolerance and
titration intolerance algorithms.Discussion
This study is the ﬁrst to develop and validate algorithms for the
identiﬁcation of SI in an administrative database. Deﬁnitions of SI
used in these algorithms align with those endorsed by the NLA
Statin Intolerance Panel [22] and the CWG [21] and are an
essential ingredient in characterizing the clinical, economic,
and quality-of-life burdens associated with SI. The algorithms
successfully identiﬁed both absolute and titration intolerance in a
population of patients at high CV risk. The algorithm for any SI
demonstrated substantial concordance (κ ¼ 0.73), sensitivity
(80.9%), PPV (75.3%), and NPV (95.4%), despite marginal perform-
ance in the absolute intolerance portion of the algorithm. In thisstudy, the titration intolerance algorithm performed best in
patients with high CV risk, as evidenced by its substantial
concordance (κ ¼ 0.78), high NPV (97.2%) and sensitivity (86.4%),
and good PPV (77.3%). There was also a higher incidence of SI in
patients with high CV risk than in patients with low CV risk.
On the basis of the results, the algorithms performed comparably
to other CV algorithms previously developed for administrative data.
Thacker et al. [28] developed an algorithm to identify patients at high
risk for coronary heart disease events (PPV 87%; sensitivity 69%;
speciﬁcity 90%). Hsieh et al. [29] validated a claims-based algorithm
to measure the incidence of acute ischemic stroke (PPV 88%;
sensitivity 97%; speciﬁcity not reported). Numerous algorithms have
been developed to identify heart failure (PPV 84%–100%; sensitivity
33%–83%) [30], whereas one study assessing CV outcomes has
reported kappa statistics ranging from 0.71 to 0.91 [31].
Both the reference deﬁnition and SI algorithms developed in
the course of this study reﬂect SI deﬁnitions of the CWG [21] and
Table 4 – Primary analysis of SI (using the complete set of AEs) by data source and risk status.
Patient population Patients deemed
statin–intolerant, n (%), in
Cohen’s
κ
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Overall
agreement
(%)
EMR Administrative
database
All eligible patients (N ¼ 990)
Any absolute intolerance 22 (2.2) 31 (3.1) 0.40 50.0 97.9 35.5 98.9 96.9
Any titration intolerance 96 (9.7) 117 (11.8) 0.74 85.4 96.1 70.1 98.4 95.1
Any SI 114 (11.5) 139 (14.0) 0.66 78.1 94.3 64.0 97.1 92.4
Patients at high CV risk (n ¼ 353)
Any absolute intolerance 11 (3.1) 10 (2.8) 0.56 54.5 98.8 60.0 98.5 97.5
Any titration intolerance 59 (16.7) 66 (18.7) 0.78 86.4 94.9 77.3 97.2 93.5
Any SI 68 (19.3) 73 (20.7) 0.73 80.9 93.7 75.3 95.4 91.2
Patients at low CV risk (n ¼ 637)
Any absolute intolerance 11 (1.7) 21 (3.3) 0.30 45.5 97.4 23.8 99.0 96.5
Any titration intolerance 37 (5.8) 51 (8.0) 0.68 83.8 96.7 60.8 99.0 95.9
Any SI 46 (7.2) 66 (10.4) 0.57 73.9 94.6 51.5 97.9 93.1
AEs, adverse effects; CV, cardiovascular; EMR, electronic medical record; NPV, negative predictive value; PPV, positive predictive value; SI, statin intolerance.
Table 5 – Secondary analysis of SI (using only musculoskeletal AEs) by data source and risk status.
Patient population Patients deemed
statin–intolerant, n (%), in
Cohen’s
κ
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Overall
agreement
(%)
EMR Administrative
database
All eligible patients (N ¼ 990)
Any absolute intolerance 19 (1.9) 29 (2.9) 0.36 47.4 97.9 31.0 99.0 97.0
Any titration intolerance 80 (8.1) 117 (11.8) 0.70 90.0 95.1 61.5 99.1 94.6
Any SI 96 (9.7) 138 (13.9) 0.62 81.3 93.3 56.5 97.9 92.1
Patients at high CV risk (n ¼ 353)
Any absolute intolerance 10 (2.8) 9 (2.5) 0.51 50.0 98.8 55.6 98.5 97.5
Any titration intolerance 50 (14.2) 66 (18.7) 0.73 90.0 93.1 68.2 98.3 92.6
Any SI 58 (16.4) 72 (20.4) 0.68 82.8 91.9 66.7 96.4 90.4
Patients at low CV risk (n ¼ 637)
Any absolute intolerance 9 (1.4) 20 (3.1) 0.26 44.4 97.5 20.0 99.2 96.7
Any titration intolerance 30 (4.7) 51 (8.0) 0.65 90.0 96.0 52.9 99.5 95.8
Any SI 38 (6.0) 66 (10.4) 0.54 78.9 94.0 45.5 98.6 93.1
AEs, adverse effects; CV, cardiovascular; EMR, electronic medical record; NPV, negative predictive value; PPV, positive predictive value; SI, statin intolerance.
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 5 2 – 8 6 0 859the NLA Statin Intolerance Panel [22] by requiring statin rechal-
lenge when appropriate clinically [19,21,22] and some evidence of
an AE during the period of statin exposure, regardless of whether
the presenting symptom was “real or perceived” [22]. In addition,
the reference EMR deﬁnition required that the documented AE be
temporal in nature and attributed to the initiation or dose
escalation of statins. Nevertheless, one element of the NLA
deﬁnition was not included in either the reference deﬁnition or
in the algorithms, that is, the requirement that one of the two
statins administered be at the lowest starting daily dose. More-
over, the SI algorithms did not require exclusion of other known
determinants of an AE, such as hypothyroidism, concurrent
illness, drug interaction, or muscle disease underlying a change
in physical activity [22]. In addition, these algorithms did not
require symptom reversal upon statin discontinuation or dose
lowering [21,22].
Although the study deﬁnitions incorporated the best consen-
sus deﬁnition available when the algorithms were developed, the
deﬁnitions of SI and the guidelines for the management of
hypercholesterolemia continue to evolve. Recently, the Interna-
tional Lipid Expert Panel proposed a uniﬁed deﬁnition of SI,
which includes statin rechallenge and a link with conﬁrmed
statin-related, muscle-based AEs [19]. Likewise, the treatment
guidelines for hypercholesterolemia changed during the course of
this study. For example, the 2013 American College of Cardiology/
American Heart Association guidelines consider rosuvastatin
10 mg a moderate-intensity statin [3], whereas in this study
rosuvastatin is classiﬁed as a high-intensity statin. Nevertheless,
rosuvastatin 10 mg has demonstrated high efﬁcacy in lowering
LDL-C (up to 52% reduction) [23,32].
The algorithms described in this report performed best in
patients at high CV risk. These patients are most likely to beneﬁt
from lipid-lowering therapy in terms of reduced CV event risk and
as such are at the greatest risk for poor outcomes as a result of
inadequate LDL-C reduction due to SI. In addition, these patients
require close monitoring, especially early in their therapy, because
statin-associated muscle AEs occur most frequently within the ﬁrst
6 months of statin therapy initiation [33]. The diagnosis of SI can,
however, be challenging because patients may be seen by clini-
cians infrequently, may not be clear in describing their symptoms
(e.g., joint pain instead of muscular pain), may minimize symptom
severity, may present atypically or with symptoms associated with
other conditions and/or medications, or may be noncompliant with
statins prescribed as part of the rechallenge. In addition, providers
may be more focused on treating other urgent health concerns. All
these scenarios may contribute to a delay in identifying and
remediating SI.
The ability to measure SI in large, real-world data sets can
expedite identiﬁcation of the predictors of SI and enable earlier,
more effective intervention. At the practice level, this could result
in a targeted intervention for patients at high risk for SI, improv-
ing patient outcomes and facilitating a more efﬁcient allocation
of valuable primary care resources. At the payer level, an
enhanced understanding of the role of SI in patient adherence
could inform both care and medication management programs.
For researchers, the present algorithm serves as the basis for the
development of more sophisticated probabilistic models.
Although standards for what constitutes adequate sensitivity,
speciﬁcity, PPV, and NPV have not yet been established, the
sensitivity associated with the absolute intolerance algorithm is
likely too low (50%) to support studies of incidence or prevalence.
In contrast, the NPV is sufﬁciently high (99%) to cull a sample of
statin users for whom there is no evidence of absolute intoler-
ance. In the absence of standards establishing minimum thresh-
olds for what constitutes a validated algorithm, researchers must
determine whether an algorithm reporting a sensitivity of 86% is
adequate to detect disease incidence or whether a PPV of 77% isadequate to cull a cohort of patients with titration intolerance.
Until such standards are established, the authors encourage
researchers to consider using sensitivity analyses as appropriate.
Researchers should consider a number of other factors before
implementing this algorithm. Algorithm performance may not be
generalizable across data sources if coding systems differ across
populations. The present study was predicated, in part, on the
deﬁnition of CV risk. Algorithm performance may vary if alter-
nate deﬁnitions of high CV risk are used.
The rate of SI observed in the present study cannot be
generalized to all statin users because the study was based on a
population of patients who had experienced at least one change
in statin therapy. Nevertheless, extrapolation to all eligible HFHS
patients suggests an overall SI rate between 4% and 6%, an
estimate that is at the lower end of the real-world range reported
for muscle-related AEs (5%–25%) [6,13–18]. Given the existing
literature and the likelihood that symptoms and diagnoses may
be underreported if such documentation on a claim will not
result in an increase in reimbursement, we believe that the
algorithms may produce a conservative estimate of SI.
Zhang et al. [17] used EMR to investigate reasons for statin
discontinuation and found that more than half of the study
patients discontinued at least one statin but that, among those
who were rechallenged, more than 90% remained actively on
statin therapy 12 months after a statin-related event. The study,
however, focused only on statin discontinuation and analyzed
only the ﬁrst-reported statin-related event. Similarly, Robison
et al. [34] used the Intermountain Healthcare EMR database to
identify patients with a documented history of SI with and
without hypothyroidism. The algorithm, however, was not vali-
dated and had numerous other limitations: patients were not
required to have a minimum duration of statin therapy; there
was no requirement to attempt therapy with more than one
statin; the analysis was conducted in a predominantly white
population; and the study did not collect information on the
speciﬁc statins taken by patients or on statin dosage.
The strength of the present study includes the ability to
compare data iteratively between a clinically rich EMR and an
administrative database. This facilitated the creation and reﬁne-
ment of algorithms to identify SI in a diverse patient population,
receiving services in various practice settings. Furthermore, the
deﬁnition of SI is comprehensive, reﬂecting the consensus state-
ment of two key organizations and incorporating important
clinical elements, such as statin rechallenge, statin intensity,
temporal AEs, and a differential threshold for patient cases with
rhabdomyolysis. Stratiﬁcation by CV-risk status revealed the
differential performance of the algorithms, which are not without
limitations. Deﬁnitions of SI in both the administrative database
and the EMR relied on sufﬁcient documentation in both data
sources. Administrative data were dependent on the documen-
tation of a symptom or a diagnosis on a claim for reimbursement,
and our gold standard EMR deﬁnition required documentation of
the symptom in the medical record. Misclassiﬁcation may also
have occurred if patients ﬁlled statin prescriptions outside of
insurance programs, if there were numerous verbal changes in
prescriptions that were not reﬂected at the pharmacy, or if
clinician concern over low LDL-C levels or patients’ ﬁnancial
constraints resulted in dosage lowering.Conclusions
The validated and comprehensive algorithms presented herein
make possible the identiﬁcation of SI from US administrative
databases. These are the ﬁrst validated algorithms for use in
administrative databases to be made available to decision
makers.
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